In contrast, the PSA-, hK2-, and FAP-based TG prodrugs at their ten-fold lower MTD (i.e., ~4 μmoles/kg/dose) stop tumor growth, but do not produce tumor regression (Figure 7). This evidence concerns the gene FAP and neoplasm.